How effective is temozolomide for treating pituitary tumours and when should it be used?
- 690 Downloads
Temozolomide (TMZ) has been shown as an effective treatment option in aggressive pituitary adenomas and carcinomas. This review analyses the published case series and demonstrates 42 % of patents show a radiological response and 27 % experience stable disease following TMZ. Prolactinomas and corticotroph tumours respond best to TMZ, showing approximately a 50 % response rate, with non-functioning tumours responding only half as frequently. Other factors that may predict the tumour’s TMZ response include MGMT and MSH status, but neither is sufficiently robust to determine treatment decisions. TMZ has an accepted role in treating pituitary carcinoma and adenomas if radiation and surgery have failed to control tumour growth. To use TMZ on the basis of anticipated future aggression, as a primary therapy, or in preference to radiotherapy remains controversial.
KeywordsPituitary Temozolomide Review Aggressive Methylguanine-DNA methyltransferase (MGMT)
- 4.Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698CrossRefPubMedGoogle Scholar
- 5.Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130–1136CrossRefPubMedGoogle Scholar
- 10.Bruno OD, Juarez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C et al (2015) Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from argentina. Int J Endocrinol Print 2015:587893Google Scholar
- 13.Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML et al (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280–E290CrossRefPubMedGoogle Scholar
- 20.Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM et al (2014) Novel MSH6 mutations in treatment-naive glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res 20(18):CrossRefPubMedGoogle Scholar